Patients With CLL Present Heterogeneously
Certain patients may present asymptomatically, affecting treatment options.
Stay updated with breaking news from Practice Guidelines. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Certain patients may present asymptomatically, affecting treatment options.
AstraZeneca's Tagrisso approved in the US for EGFRm non-small cell lung cancer with chemotherapy. FLAURA2 trial results show significant benefit.
This review summarizes current utilization of anti-HER2 targeted therapy across several non-breast solid tumors in the setting of advanced disease.
Highlights: Robust economics: pre-tax net present value (“NPV”) of C$1.53 billion, post-tax NPV of C$910 million, pre-tax internal rate of...
Treatment options are distinct in their mechanisms, safety profiles, and implications for patients’ quality of life.